CAR T Promises Longer Relief For Myasthenia Gravis

(Posted on Saturday, February 14, 2026)

For the first time, people living with myasthenia gravis may have the chance for long-lasting remission after a short treatment—rather than a lifetime of daily drugs, hospital visits and lingering symptoms. A new trial of the mRNA-based CAR T-cell therapy Descartes‑08 found that most patients enjoyed a year or more of significant relief after just six weeks of infusions. This breakthrough could shift the treatment paradigm for this chronic autoimmune disease.

Myasthenia gravis is an autoimmune disease in which the immune system targets the connections between nerves and muscles. This leads to symptoms such as drooping eyelids, difficulty swallowing or speaking and serious breathing problems. Most patients rely on daily medications, long-term steroids or immunosuppressant drugs. Severe cases may require frequent hospital-based treatments. Newer biologic therapies provide additional options but require ongoing infusions and are associated with high costs and side effects. Many patients do not achieve adequate control with current treatments, highlighting the need for more effective approaches.

A New Kind Of Treatment For Myasthenia Gravis

Current therapies focus on short-term symptom relief or long-term immune suppression, often at the cost of side effects like weight gain, diabetes, infection and mood changes. Targeted biologics offer more precise control but demand ongoing infusions and high costs. All these strategies regard myasthenia gravis as a lifelong condition that requires frequent interventions and complex treatment plans.

CAR T therapy aims for a different outcome: a time-limited intervention that may reset the immune system, allowing patients to experience minimal symptoms for months or years without ongoing medication. To achieve this, CAR T-cell therapy employs a distinct strategy. Clinicians collect a patient’s T cells, which are white blood cells involved in immune responses, and modify them in the laboratory using a chimeric antigen receptor or CAR. This receptor directs T cells to identify and remove plasma cells that produce antibodies responsible for myasthenia gravis.

The treatment uses mRNA technology, similar to that used in COVID‑19 vaccines, to provide temporary instructions for T cells to target cells expressing BCMA, a protein found on antibody-producing plasma cells. The mRNA-based approach ensures that the engineered T cells remain active only for a limited period. This reduces the risk of long-term complications and removes the need for chemotherapy before treatment. Therefore, the therapy is more suitable for patients without cancer.

What The Trial Found On Symptoms And Safety

Approximately two-thirds of participants who received the treatment showed a strong response at three months, compared to one-quarter in the placebo group. By six months, 57% of patients who received the treatment had minimal symptoms, with little or no daily impairment. Patients reported increased energy, improved muscle strength and greater ability to work, eat and perform daily activities without concern for sudden weakness. Most maintained these benefits for up to twelve months. This indicates that this therapy may provide sustained improvement rather than only short-term relief.

In this trial, most side effects were mild, such as brief fevers or chills. There were no serious neurological or immune complications, and laboratory results did not show significant reductions in immune cells or loss of vaccine protection. Previous studies reported similar safety profiles. These findings indicate that mRNA-based CAR T therapy may provide substantial benefits with a safety profile suitable for outpatient care.

Where CAR T Fits In The Future Of Care

The Descartes‑08 treatment is one of several worldwide efforts to adapt CAR T-cell therapies for autoimmune diseases. Other research groups are evaluating CAR T cells that target both BCMA and CD19, with some patients achieving remission without medication for at least a year. Additional experimental approaches are under investigation to improve precision. CAR T therapy is now being considered as a potential addition to biologics and small molecules in the future management of myasthenia gravis.

Several questions must be addressed before CAR T therapy can become widely used. The trial included a small number of participants, and larger, longer-term studies are necessary to confirm the findings, the need for retreatment and long-term safety. Also, manufacturing is complex and costly. This currently limits access to major medical centers and raises concerns about equitable availability.

Despite these challenges, the study represents a significant development. This CAR T-cell therapy may allow many patients with myasthenia gravis to experience minimal symptoms for a year or longer following a brief outpatient treatment. For patients, this signals progress toward treatments that restore function and stability, rather than only managing symptoms.